33 Results for "

CDK4-IN-4

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "CDK4-IN-4" in MCE Product Catalog:

Cat. No.: HY-171740
CAS No.: 3027994-03-9
Target:  

CDK

Research Areas:  

Cancer

CDK4-IN-4 (example 30) is a selective CDK4 inhibitor (IC50<10 nM) that can be used in cancer research .
loading...
    loading...
7
7 Publications Verification
Cat. No.: HY-11009
CAS No.: 164658-13-3
Purity:  98.90%
Target:  

CDK PKC

Research Areas:  

Cancer

CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-18299A
CAS No.: 212844-53-6
Synonyms: NG-60
Target:  

CDK Autophagy Apoptosis

Research Areas:  

Cancer

Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-16559
CAS No.: 920113-03-7
Synonyms: P276-00
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10014
CAS No.: 741713-40-6
Purity:  99.57%
Target:  

CDK GSK-3 Apoptosis

Research Areas:  

Cancer

R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-111361
CAS No.: 1429515-59-2
Purity:  98.72%
Synonyms: LT-171-861
Target:  

CDK FLT3

Research Areas:  

Cancer

FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103380
CAS No.: 141992-47-4
Purity:  98.58%
Target:  

CDK

Research Areas:  

Cancer

NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC50 of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 .
loading...
    loading...
Cat. No.: HY-136726
CAS No.: 359886-84-3
Purity:  98.12%
Synonyms: CINK4
Target:  

CDK

Research Areas:  

Cancer

GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC50s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer .
loading...
    loading...
Cat. No.: HY-15612
CAS No.: 1256963-02-6
Target:  

CDK

Research Areas:  

Cancer

CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
loading...
    loading...
Cat. No.: HY-P1109
CAS No.: 189064-08-2
Target:  

CDK

Research Areas:  

Cancer

[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both cdk4 and cdk6 and inhibits cdk4-cyclin D1 kinase activity in vitro (IC50: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .
loading...
    loading...
Cat. No.: HY-153088
CAS No.: 1169694-98-7
Target:  

CDK

Research Areas:  

Cancer

CDK4/6-IN-16 (example 195) is a potent CDK4 and CDK6 inhibitor, with an IC50 of 0.013 μM for CDK4. CDK4/6-IN-16 can be used for the research of CDK4-mediated disorders, such as cancer .
loading...
    loading...
Cat. No.: HY-108907
CAS No.: 1446715-47-4
Target:  

Casein Kinase

Research Areas:  

Cancer

SR-1277 is a potent, selective and ATP competitive CK1δ/ε inhibitor, with IC50s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC50s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-16559A
CAS No.: 920113-02-6
Synonyms: P276-00 free base
Target:  

CDK

Research Areas:  

Cancer

Riviciclib (P276-00 free base) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib shows antitumor activity on cisplatin-resistant cells .
loading...
    loading...
Cat. No.: HY-112450
CAS No.: 500735-47-7
Target:  

CDK

Research Areas:  

Cancer

Olomoucine II is a potent CDK inhibitor with IC50 values of 0.06, 0.1, 0.45, 7.6, 19.8 µM for CDK9/cyclin T, CDK2/cyclin E, CDK7/cyclin H, CDK1/cyclin B, CDK4/cyclin D1, respectively. Olomoucine II shows antiproliferative activity .
loading...
    loading...
Cat. No.: HY-147409
CAS No.: 2075750-05-7
Target:  

CDK

Research Areas:  

Cancer

Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .
loading...
    loading...
Cat. No.: HY-172234
CAS No.: 2516247-98-4
Target:  

CDK

Research Areas:  

Cardiovascular Disease Cancer

PF-06842874 is a CDK4/Cyclin D1 and CDK6/Cyclin D3 inhibitor (Ki values are 62 and 130 nM, respectively). PF-06842874 can be used in the research of pulmonary arterial hypertension and cancer .
loading...
    loading...
Cat. No.: HY-111932
CAS No.: 244021-67-8
Target:  

CDK GSK-3

Research Areas:  

Cancer

Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively . Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β .
loading...
    loading...
Cat. No.: HY-111207
CAS No.: 883561-04-4
Purity:  99.94%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

CA224 (Compound 1) is a selective and orally active Cdk4–cyclin D1 inhibitor with an IC50 of 6.2 µM. CA224 induces cell apoptosis and shows antitumor activity .
loading...
    loading...
Cat. No.: HY-E70681
Target:  

CDK

Research Areas:  

Cancer

CDK4 has a well-established role in cell-cycle controland CDK4-cyclin complexes are commonly deregulated in tumorigenesis. CDK4/CycD1 Recombinant Human Active Protein Kinase is an ortholog of CDK4 .
loading...
    loading...
Cat. No.: HY-E70682
Target:  

CDK

Research Areas:  

Cancer

CDK4 has a well-established role in cell-cycle controland CDK4-cyclin complexes are commonly deregulated in tumorigenesis. CDK4/CycD2 Recombinant Human Active Protein Kinase is an ortholog of CDK4 .
loading...
    loading...